Search Result

Results for "

AMPA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (2) Apoptosis (19) c-Met/HGFR (2) Calcium Channel (8) CaMK (1) Carbonic Anhydrase (6) Cytochrome P450 (2) Endogenous Metabolite (17) Ferroptosis (16) GABA Receptor (6) Glutaminase (2) iGluR (140) Isotope-Labeled Compounds (6) Lipoxygenase (1) LPL Receptor (1) mGluR (2) mTOR (1) Phosphatase (1) PKC (1) Potassium Channel (6) Sodium Channel (7) Somatostatin Receptor (2) TRP Channel (2) Tyrosinase (2)
By Research Areas:	Cancer (8) Cardiovascular Disease (3) Inflammation/Immunology (2) Metabolic Disease (3) Neurological Disease (142)

By Targets:

Adrenergic Receptor (2)

Apoptosis (19)

c-Met/HGFR (2)

Calcium Channel (8)

CaMK (1)

Carbonic Anhydrase (6)

Cytochrome P450 (2)

Endogenous Metabolite (17)

Ferroptosis (16)

GABA Receptor (6)

Glutaminase (2)

iGluR (140)

Isotope-Labeled Compounds (6)

Lipoxygenase (1)

LPL Receptor (1)

mGluR (2)

mTOR (1)

Phosphatase (1)

PKC (1)

Potassium Channel (6)

Sodium Channel (7)

Somatostatin Receptor (2)

TRP Channel (2)

Tyrosinase (2)

By Research Areas:

Cancer (8)

Cardiovascular Disease (3)

Inflammation/Immunology (2)

Metabolic Disease (3)

Neurological Disease (142)

152

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136275

AMPA receptor modulator-2	iGluR	Others
AMPA receptor modulator-2 (Example 134) is a AMPA receptor modulator, with a pIC₅₀ of 10.1 for TARPγ8 dependent AMPA receptor . pIC₅₀ = -lgIC₅₀.

HY-122150

AMPA receptor modulator-3	iGluR	Neurological Disease
AMPA receptor modulator-3 is an allosteric *AMPA* receptor modulator (EC₅₀: 4.4 μM). AMPA receptor modulator-3 can be used in the research of mammalian nervous system, such as learning and memory .

HY-161090

AMPA receptor modulator-7	iGluR	Neurological Disease
AMPA receptor modulator-7 (compound 36) is a modulator of AMPA receptor. AMPA receptor modulator-7 has oral activity and can penetrate the blood-brain barrier .

HY-145959

AMPA receptor antagonist-3	iGluR	Neurological Disease
AMPA receptor antagonist-3 is an AMPA receptor antagonist extracted from patent US20070027143A1. AMPA receptor antagonist-3 can be used for the research of central nervous system disorders .

HY-145761

AMPA-IN-1	iGluR	Neurological Disease
AMPA-IN-1 is a potent inhibitor of *AMPA* receptor. AMPA receptors are receptors that are widely expressed in the brain, and play a central role in the regulation of fast excitatory synaptic transmission and synaptic plasticity. AMPA-IN-1 has the potential for the research of various central diseases including epilepsy (extracted from patent WO2017082288A1, compound 14) .

HY-149975

AMPA receptor modulator-4	iGluR	Neurological Disease
AMPA receptor modulator-4, a 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (BTD), is an orally active positive allosteric modulator of the AMPA receptors (AMPAR PAMs). AMPA receptor modulator-4 can cross the blood-brain barrier. AMPA receptor modulator-4 increases the cognition performance and improves working memory performance in mice .

HY-154798

AMPA receptor modulator-5	iGluR	Neurological Disease
AMPA receptor modulator-5 (Example 217) is an AMPA receptor modulator. AMPA receptor modulator-5 can be used for research of neurological disease .

HY-155628

AMPA receptor modulator-6	iGluR	Others
AMPA receptor modulator-6 is an *AMPA* receptor positive allosteric modulator (PAM). AMPA receptor modulator-6 can be used in the study of neurological diseases .

HY-136905

AMPA receptor antagonist-2	iGluR	Others
AMPA receptor antagonist-2 (example 23) is an AMPA receptor antagonist .

HY-112699

AMPA receptor modulator-1	iGluR	Neurological Disease
AMPA receptor modulator-1 is a potent, orally active and selective AMPAR regulatory protein TARP γ-8 negative modulator with a pIC₅₀ of 9.7, more selective over GluA1/γ-2 (pIC₅₀=5) .

HY-100815A

(S)-AMPA L-AMPA	iGluR	Neurological Disease
(S)-AMPA (L-AMPA), an active S-enantiomer of AMPA, is a potent and selective AMPA receptor agonist .

HY-103235

NPEC-caged-(S)-AMPA	iGluR	Neurological Disease
NPEC- caged-(S)-AMPA, a caged neurotransmitter analog, is a NPEC photoprotecting group caged the (S)-AMPA (HY-100815A) to make caged ligands specific for glutamate receptor sub-types. NPEC- caged-(S)-AMPA selectively activates AMPA receptor .

HY-100815B

(RS)-AMPA (±)-AMPA	iGluR	Neurological Disease
(RS)-AMPA ((±)-AMPA) is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA does not interfere with binding sites for kainic acid or NMDA receptors .

HY-100815D

*(RS)-AMPA* monohydrate** (±)-AMPA monohydrate	iGluR	Neurological Disease
(RS)-AMPA ((±)-AMPA) monohydrate is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA monohydrate does not interfere with binding sites for kainic acid or NMDA receptors .

HY-100815E

*(RS)-AMPA* hydrochloride** (±)-AMPA hydrochloride	iGluR	Neurological Disease
(RS)-AMPA ((±)-AMPA) hydrochloride is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA hydrobromide does not interfere with binding sites for kainic acid or NMDA receptors .

HY-100815C

*(RS)-AMPA* hydrobromide** (±)-AMPA hydrobromide	iGluR	Neurological Disease
(RS)-AMPA ((±)-AMPA) hydrobromide is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA hydrobromide does not interfere with binding sites for kainic acid or NMDA receptors .

HY-100815

(R)-AMPA	iGluR	Neurological Disease
(R)-AMPA is an inactive AMPA receptor ligand that inhibits the release of excitatory amino acids from neurons. (R)-AMPA is inactive in experiments that enhance the release of [3H]D-aspartate induced by electrical stimulation. (R)-AMPA is inhibited by competitive and noncompetitive AMPA receptor selective antagonists in response to AMPA and glutamate .

HY-163097

ZCAN262	iGluR	Neurological Disease
ZCAN262 (compound 6 ) is an *AMPA* modulator. ZCAN262 prevents AMPA-mediated excitotoxicity by targeting an allosteric binding site .

HY-129030

BDZ-g	iGluR	Neurological Disease
BDZ-g is a potent, selective antagonist of *AMPA* receptor. BDZ-g has the potential for the research of various neurological disorders involving excessive activity of AMPA receptors .

HY-101165

Cyclothiazide	iGluR	Neurological Disease
Cyclothiazide, a positive allosteric modulator of AMPA receptors, is used frequently to block the desensitization of both native and heterologously expressed AMPA receptors. Cyclothiazide is known to produce a fast inhibition of AMPA receptor desensitization and a much slower potentiation of the AMPA current .

HY-10935

LY450108 1 Publications Verification	iGluR	Neurological Disease
LY450108 is a potent *AMPA* receptor potentiator. LY450108 has the potential for depression and Parkinson's disease research .

HY-101165R

Cyclothiazide (Standard)	iGluR	Neurological Disease
Cyclothiazide (Standard) is the analytical standard of Cyclothiazide. This product is intended for research and analytical applications. Cyclothiazide, a positive allosteric modulator of AMPA receptors, is used frequently to block the desensitization of both native and heterologously expressed AMPA receptors. Cyclothiazide is known to produce a fast inhibition of AMPA receptor desensitization and a much slower potentiation of the AMPA current .

HY-106039

LY 215490	iGluR	Neurological Disease
LY 215490 is a selective, competitive AMPA receptor antagonist against *AMPA, CGSl9755* and kainate with IC₅₀ values of 4.8, 26.4 and 247 μM, respectively. LY 215490 shows neuroprotective effects in focal ischaemia .

HY-100785A

gamma-DGG acetate γDGG acetate; γ-D-Glutamylglycine acetate	iGluR	Neurological Disease
gamma-DGG acetate (γDGG acetate) is a competitive AMPA receptor blocker. gamma-DGG acetate is also a reversible Excitatory post-synaptic potentials (e.p.s.p.s) antagonist .

HY-118814

YM928	iGluR	Neurological Disease
YM928 is an orally active and noncompetitive α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid *(AMPA) receptor* antagonist. YM928 inhibits AMPA receptor-mediated toxicity in primary rat hippocampal cultures with an IC₅₀ value of 2 μM. YM928 blocks AMPA-induced intracellular calcium influx with an IC₅₀ value of 3 μM and antagonizes AMPA-induced inward currents with an IC₅₀ value of 1 μM. YM928 is promising for research of neurological disorders .

HY-120811

PF-04701475	iGluR	Neurological Disease
PF-04701475 is a potent AMPA receptor potentiator with an EC₅₀ of 123 nM. PF-04701475 can be used for the study of neurological disorders .

HY-122742

HBT1	iGluR	Neurological Disease
HBT1 is a potent α-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor (AMPA-R) potentiator. HBT1 bonds with S518 in the ligand-binding domain (LBD) of AMPA-R in a glutamate-dependent manner. HBT1 did not show remarkable bell-shaped response in brain-derived neurotrophic factor (BDNF) production in primary neurons .

HY-124539

ZK 187638	iGluR	Neurological Disease
ZK 187638 is an AMPA receptor antagonist. ZK 187638 antagonizes the kainate-induced currents in cultured hippocampal neurons with an IC₅₀ of 3.4 μM in a noncompetitive fashion .

HY-W922811

DL-Willardiine	Others	Neurological Disease
DL-Willardiine is an *AMPA* antagonist with an IC₅₀ of 2 μM. DL-Willardiine can be utilized in psychotropic cccccc research .

HY-15071

YM90K	iGluR	Neurological Disease
YM90K is a potent and selective AMPA receptor antagonist with a K_i of 84 nM. YM90K is less potent in inhibiting kainate (K_i of 2.2 μM) and NMDA (K_i of 37 μM) receptors. YM90K has neuroprotective actions .

HY-105860

Selurampanel BGG 492	iGluR	Neurological Disease
Selurampanel (BGG 492) is an orally active and competitive AMPA receptor antagonist with an IC₅₀ of 190 nM. Selurampanel has reasonable blood-brain barrier penetration. Selurampanel can be used for epilepsy research .

HY-122164

LY-503430	iGluR	Neurological Disease
LY-503430 is an orally active AMPA receptor positive allosteric modulator (PAM). LY-503430 can be used for the study of Parkinson's disease .

HY-15066

CNQX 5+ Cited Publications FG9065	iGluR	Neurological Disease
CNQX (FG9065) is a potent and competitive AMPA/kainate receptor antagonist with IC₅₀s of 0.3 μM and 1.5 μM, respectively. CNQX is a competitive non-NMDA receptor antagonist . CNQX blocks the expression of fear-potentiated startle in rats .

HY-10933

CX516 2 Publications Verification BDP 12	iGluR	Neurological Disease
CX516 (BDP 12) is an ampakine and acts as an *AMPA* receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI) .

HY-15066A

CNQX disodium 5+ Cited Publications FG9065 disodium	iGluR	Neurological Disease
CNQX disodium (FG9065 disodium) is a potent and competitive AMPA/kainate receptor antagonist with IC₅₀s of 0.3 μM and 1.5 μM, respectively. CNQX disodium is a competitive non-NMDA receptor antagonist . CNQX disodium blocks the expression of fear-potentiated startle in rats .

HY-107606

UBP301	iGluR	Neurological Disease
UBP301 is a potent and selective antagonist of kainate receptor with IC₅₀ and K_D of 164 μM and 5.94 μM, respectively. UBP301 has ∼30-fold selectivity of kainate receptor over AMPA receptor. UBP301 is the derivative of willardiine .

HY-107606A

UBP301 hydrochloride	iGluR	Neurological Disease
UBP301 hydrochloride is a potent and selective antagonist of kainate receptor with IC₅₀ and K_D of 164 μM and 5.94 μM, respectively. UBP301 hydrochloride has ～30-fold selectivity of kainate receptor over AMPA receptor. UBP301 hydrochloride is the derivative of willardiine .

HY-108497

L-803087	Somatostatin Receptor	Neurological Disease Cancer
L-803087 is a potent and selective somatostatin sst4 receptor agonist with a K_i of 0.7 nM. L-803087 is >280-fold higher than other somatostatin receptors. L-803087 facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice .

HY-15078

NS1219 (R)-SPD502	iGluR	Neurological Disease
NS1219 ((R)-SPD502) is the isomer of NS 1209 HY-15074. NS1209 is a selective AMPA receptor antagonist with neuroprotective activity. NS1209 can be used for the research of stroke, neuropathic pain and epilepsy .

HY-106467B

Caroverine hydrochloride	iGluR	Neurological Disease
Caroverine hydrochloride is a potent, competitive and reversible antagonist of NMDA and AMPA glutamate receptor. Caroverine hydrochloride is also an antioxidant and calcium-blocking agent that exhibits vasorelaxant action. Caroverine hydrochloride can be used for the research of inner ear tinnitus .

HY-106467

Caroverine	iGluR	Neurological Disease
Caroverine is a potent, competitive and reversible antagonist of NMDA and AMPA glutamate receptor. Caroverine is also an antioxidant and calcium-blocking agent that exhibits vasorelaxant action. Caroverine can be used for the research of inner ear tinnitus .

HY-118424

JNJ-55511118	iGluR	Neurological Disease
JNJ-55511118 is a highly potent, reversible, and selective AMPA receptor inhibitor selective for TARP-γ8. JNJ-55511118 fully displaces the radioligand (20 nM) with the K_i of 26 nM in competition binding experiments. JNJ-55511118 is a tool molecule with potential therapeutic utility as an anticonvulsant or neuroprotectant .

HY-108497A

L-803087 TFA	Somatostatin Receptor	Neurological Disease Cancer
L-803087 TFA is a potent and selective somatostatin sst4 receptor agonist with a K_i of 0.7 nM. L-803087 TFA is >280-fold more selective for sst4 receptor than other somatostatin receptors. L-803087 TFA facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice .

HY-110175

CX614	iGluR	Neurological Disease
CX614 is a positive variant modulator of AMPA receptors that enhances excitatory postsynaptic potentials (amplitude and duration) by blocking and slowing the inactivation of responses to glutamate and automatically evokes excitatory postsynaptic currents in neuronal cultures. CX614 can be used in the study of psychiatric disorders such as depression .

HY-19432

UBP-282	iGluR	Neurological Disease
UBP-282 is a potent, selective and competitive *AMPA* and kainate receptor antagonist. UBP-282 inhibits the fast component of the dorsal root-evoked ventral root potential (fDR-VRP) with an IC₅₀ value of 10.3 μM. UBP-282 antagonizes kainate-induced depolarisations of dorsal roots with a pA₂ value of 4.96 .

HY-101528

IDRA 21	iGluR	Neurological Disease
IDRA 21 is a positive and orally active modulator of the *AMPA* receptor. IDRA 21 facilitates excitatory neurotransmission via GluR1/2 receptors. IDRA 21 has the potential for the research of cognitive/memory disorders, including those associated with aging .

HY-110234

Topiramate D12 McN 4853 D12 ; RWJ 17021 D12	iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase	Neurological Disease
Topiramate D12 (McN 4853 D12) is a deuterium labeled Topiramate. Topiramate is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of *kainate/AMPA* receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-103234A

GYKI 52466 dihydrochloride	iGluR	Neurological Disease
GYKI 52466 dihydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC₅₀ values of 7.5 and 11μM, respectively. GYKI 52466 dihydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 dihydrochloride can be used in Parkinson's disease research .

HY-103234

GYKI 52466	iGluR	Neurological Disease
GYKI 52466 is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC₅₀ values of 7.5 and 11μM, respectively. GYKI 52466 has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 can be used in Parkinson's disease research .

HY-103234B

GYKI 52466 hydrochloride	iGluR	Neurological Disease
GYKI 52466 hydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC₅₀ values of 7.5 and 11μM, respectively. GYKI 52466 hydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 hydrochloride can be used in Parkinson's disease research .

Cat. No.	Product Name	Target	Research Area

HY-P3355

p-fin4	iGluR	Neurological Disease
p-fin4 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 0.4 μM. p-fin4 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p-fin4 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .

HY-P3340

Leptin (116-130)	iGluR	Neurological Disease
Leptin (116-130) is a bioactive leptin fragment. Leptin (116-130) promotes AMPA receptor trafficking to synapses and facilitate activity-dependent hippocampal synaptic plasticity. Leptin (116-130) prevents hippocampal synaptic disruption and neuronal cell death in models of amyloid toxicity. Leptin (116-130) has the potential for the research of Alzheimer's disease (AD) .

HY-P3354

p3Ysh-3	iGluR	Neurological Disease
p3Ysh-3 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 1.09 μM. p3Ysh-3 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p3Ysh-3 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .

HY-P5487

GluR23Y	iGluR	Others
GluR23Y is a biological active peptide. (This GluR23Y peptide was used in ELISA cell-surface assay for the insulin-stimulated endocytosis of native AMPA receptors in cultured hippocampal neurons. GluR23Y prevented any insulin-induced reduction. The blockade of insulin action was observed when the GluR23Y peptide was delivered into neurons by fusing it to the membrane transduction domain of HIV-1.)

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-14608

L-Glutamic acid Maximum Cited Publications 8 Publications Verification	Structural Classification Microorganisms Source classification Disease markers Endocrine diseases Amino acids Nervous System Disorder Endogenous metabolite Cardiovascular System Disorder Cancer	Endogenous Metabolite iGluR Ferroptosis Apoptosis
L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases. L-Glutamic acid acts at ionotropic and metabotropic glutamate receptors .

HY-N3298

Meranzin	Cardiovascular Disease other families Classification of Application Fields Neurological Disease Source classification Coumarins Phenylpropanoids Plants Disease Research Fields	Adrenergic Receptor
Meranzin is an absorbed bioactive compound from the Traditional Chinese Medicine (TCM) Chaihu-Shugan-San (CSS). Meranzin, isolated from leaves of Murraya exotica L., regulates the shared alpha 2-adrenoceptor and involves the AMPA-ERK1/2–BDNF signaling pathway. Meranzin has the potential for the prevention of the comorbidity of atherosclerosis and depression .

HY-12597

Quisqualic acid L-Quisqualic acid	Structural Classification Ketones, Aldehydes, Acids Combretaceae Source classification Plants Quisqualis indica Linn.	iGluR mGluR
Quisqualic acid (L-Quisqualic acid), a natural analog of glutamate, is a potent and pan two subsets (iGluR and mGluR) of excitatory amino acid (EAA) agonist with an EC₅₀ of 45 nM and a K_i of 10 nM for mGluR1R. Quisqualic acid is isolated from the fruits of Quisqualis indica .

HY-14608A

L-Glutamic acid monosodium salt Maximum Cited Publications 8 Publications Verification	Structural Classification Microorganisms other families Animals Source classification Amino acids Plants	iGluR Apoptosis Ferroptosis Endogenous Metabolite
L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases. L-Glutamic acid monosodium salt acts at ionotropic and metabotropic glutamate receptors .

HY-W015309

Decanoic acid 1 Publications Verification	Structural Classification Microorganisms Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Biological Pesticide Research Agricultural Research	iGluR Tyrosinase c-Met/HGFR Glutaminase Endogenous Metabolite
Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of *AMPA* receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

HY-14608R

L-Glutamic acid (Standard)	Structural Classification Microorganisms Source classification Disease markers Endocrine diseases Amino acids Nervous System Disorder Endogenous metabolite Cardiovascular System Disorder Cancer	Endogenous Metabolite iGluR Ferroptosis Apoptosis
L-Glutamic acid (Standard) is the analytical standard of L-Glutamic acid. This product is intended for research and analytical applications. L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases . IC₅₀ & Target:DA . In Vitro: L-Glutamic acid (120, 500, 750, 1000 mg/dL) can reduce the harmful effect of lithium on the embryonic development of Xenopus Xenopus . L-Glutamic acid (2, 5, 10, 20 mM, 24-48 h) can induce neuroexcitotoxicity in neuroblastoma . In Vivo: L-Glutamic acid (3 g/kg, subcutaneous injection) can promote excitotoxic degeneration of retinal ganglion cells in mice . L-Glutamic acid (750 mg/kg, intraperitoneal injection) can reduce and inhibit oxidative stress induced by chlorpyrifos (CPF) in rats .

HY-14608AR

L-Glutamic acid (monosodium salt) (Standard)	Structural Classification Microorganisms other families Animals Source classification Amino acids Plants	iGluR Apoptosis Ferroptosis Endogenous Metabolite
L-Glutamic acid (monosodium salt) (Standard) is the analytical standard of L-Glutamic acid (monosodium salt). This product is intended for research and analytical applications. L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases .

HY-N3298R

Meranzin (Standard)	Structural Classification other families Source classification Coumarins Phenylpropanoids Plants	Adrenergic Receptor
Meranzin (Standard) is the analytical standard of Meranzin. This product is intended for research and analytical applications. Meranzin is an absorbed bioactive compound from the Traditional Chinese Medicine (TCM) Chaihu-Shugan-San (CSS). Meranzin, isolated from leaves of Murraya exotica L., regulates the shared alpha 2-adrenoceptor and involves the AMPA-ERK1/2–BDNF signaling pathway. Meranzin has the potential for the prevention of the comorbidity of atherosclerosis and depression .

HY-W015309R

Decanoic acid (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	iGluR Tyrosinase c-Met/HGFR Glutaminase
Decanoic acid (Standard) is the analytical standard of Decanoic acid. This product is intended for research and analytical applications. Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

HY-116330AR

Hyperforin dicyclohexylammonium salt (Standard)	Structural Classification Natural Products Guttiferae Source classification Hyperlcurn perforatum L. Plants	TRP Channel Calcium Channel
Hyperforin (dicyclohexylammonium salt) (Standard) is the analytical standard of Hyperforin (dicyclohexylammonium salt). This product is intended for research and analytical applications. Hyperforin dicyclohexylammonium salt (Hyperforin DCHA) is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin dicyclohexylammonium salt modulates Ca2+ levels by activating Ca2+-conducting non-selective canonical TRPC6 channels. Hyperforin dicyclohexylammonium salt also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin dicyclohexylammonium salt modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .

Cat. No.	Product Name	Chemical Structure

HY-W015309S

Decanoic acid-d3
Decanoic acid-d₃ is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects[1][2][3].

HY-W015309S1

Decanoic acid-d19
Decanoic acid-d₁₉9 is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects[1][2][3].

HY-W015309S3

Decanoic acid-d5
Decanoic acid-d₅ is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects[1][2][3].

HY-14608S7

L-Glutamic acid-d5
L-Glutamic acid-d₅ is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S8

L-Glutamic acid-d3
L-Glutamic acid-d₃ is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S5

L-Glutamic acid-13C5
L-Glutamic acid- ¹³C₅ is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S2

L-Glutamic acid-15N
L-Glutamic acid- ¹⁵N is the ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals[1].

HY-W015309S2

Decanoic acid-d2
Decanoic acid-d₂ is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects[1][2][3].

HY-10933S

CX516-d10
CX516-d₁₀ is the deuterium labeled CX516. CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI)[1].

HY-14608S

L-Glutamic acid-13C
L-Glutamic acid- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S1

L-Glutamic acid-1-13C
L-Glutamic acid-1- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S6

L-Glutamic acid-5-13C
L-Glutamic acid-5- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S3

L-Glutamic acid-13C5,15N
L-Glutamic acid- ¹³C₅, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S9

L-Glutamic acid-15N,d5
L-Glutamic acid- ¹⁵N,d₅ is the deuterium and ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S10

L-Glutamic acid-13C2
L-Glutamic acid- ¹³C₂ is the ¹³C labeled L-Glutamic acid[1]. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals[2].

HY-14608S4

L-Glutamic acid-13C5,15N,d5
L-Glutamic acid- ¹³C₅, ¹⁵N,d₅ is the deuterium, ¹³C-, and 15-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-B0122S

Topiramate-13C6

Topiramate-13C6 (McN 4853-13C6) is the ¹³C labeled isotope of Topiramate (HY-B0122). Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82336

	*Phospho-Glutamate Receptor 1 (AMPA* Subtype) (Ser845) Antibody (YA2081)** GRIA1; GLUH1; GLUR1; Glutamate receptor 1; GluR-1; AMPA-selective glutamate receptor 1; GluR-A; GluR-K1; Glutamate receptor ionotropic; AMPA 1; GluA1	WB	Human, Rat
	Phospho-Glutamate Receptor 1 (AMPA Subtype) (Ser845) Antibody (YA2081) is a biotin-conjugated non-conjugated IgG antibody, targeting Phospho-Glutamate Receptor 1 (AMPA Subtype) (Ser845), with a predicted molecular weight of 102 kDa (observed band size: 102 kDa). Phospho-Glutamate Receptor 1 (AMPA Subtype) (Ser845) Antibody (YA2081) can be used for WB experiment in human, rat background.

HY-P81398

	Ionotropic Glutamate Receptor 2 Antibody (YA1143) GRIA2; GLUR2; Glutamate receptor 2; GluR-2; AMPA-selective glutamate receptor 2; GluR-B; GluR-K2; Glutamate receptor ionotropic; AMPA 2; GluA2	IHC-P	Human
	Ionotropic Glutamate Receptor 2 Antibody (YA1143) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1143), targeting Ionotropic Glutamate Receptor 2. Ionotropic Glutamate Receptor 2 Antibody (YA1143) can be used for IHC-P experiment in human background.

HY-P82144

	GluA4 Antibody (YA1889) AMPA4; GluA4; GluR4; GLUR4C; GLURD; Gria4	WB, FC	Human, Mouse, Rat
	GluA4 Antibody (YA1889) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1889), targeting GluA4, with a predicted molecular weight of 101 kDa (observed band size: 101 kDa). GluA4 Antibody (YA1889) can be used for WB, FC experiment in human, mouse, rat background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks